Metabolic syndrome as a peculiar target for management of prostate cancer patients

Vincenza Conteduca, Giuseppe Di Lorenzo, Giovanni Bozza, Raffaele Ardito, Michele Aieta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalClinical Genitourinary Cancer
Volume11
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Prostatic Neoplasms
Metformin
Hyperinsulinism
Sirolimus
Body Composition
Androgens
Insulin Resistance
Epidemiologic Studies
Prostate
Neoplasms
Intercellular Signaling Peptides and Proteins
Insulin
Drug Therapy
Therapeutics

Keywords

  • Androgen deprivation therapy
  • Carcinogenesis
  • Hyperinsulinemia
  • Insulin-growth factor-1
  • Metformin

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Metabolic syndrome as a peculiar target for management of prostate cancer patients. / Conteduca, Vincenza; Di Lorenzo, Giuseppe; Bozza, Giovanni; Ardito, Raffaele; Aieta, Michele.

In: Clinical Genitourinary Cancer, Vol. 11, No. 3, 09.2013, p. 211-220.

Research output: Contribution to journalArticle

Conteduca, Vincenza ; Di Lorenzo, Giuseppe ; Bozza, Giovanni ; Ardito, Raffaele ; Aieta, Michele. / Metabolic syndrome as a peculiar target for management of prostate cancer patients. In: Clinical Genitourinary Cancer. 2013 ; Vol. 11, No. 3. pp. 211-220.
@article{1ebc296205ac471ca60912cd38369b8e,
title = "Metabolic syndrome as a peculiar target for management of prostate cancer patients",
abstract = "An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.",
keywords = "Androgen deprivation therapy, Carcinogenesis, Hyperinsulinemia, Insulin-growth factor-1, Metformin",
author = "Vincenza Conteduca and {Di Lorenzo}, Giuseppe and Giovanni Bozza and Raffaele Ardito and Michele Aieta",
year = "2013",
month = "9",
doi = "10.1016/j.clgc.2013.04.009",
language = "English",
volume = "11",
pages = "211--220",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Metabolic syndrome as a peculiar target for management of prostate cancer patients

AU - Conteduca, Vincenza

AU - Di Lorenzo, Giuseppe

AU - Bozza, Giovanni

AU - Ardito, Raffaele

AU - Aieta, Michele

PY - 2013/9

Y1 - 2013/9

N2 - An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.

AB - An interesting and reciprocal association between the metabolic syndrome and prostate cancer has been identified. Metabolic alterations, such as hyperinsulinemia, increased levels of insulin growth factor-1, and insulin resistance could be on the basis of development and progression of many tumors, including prostate cancer, and changes in body composition, in turn, can represent some side effects of androgen deprivation therapy and novel drugs, such as mammalian target of rapamycin inhibitors. This review evaluates this interrelation between metabolic syndrome and prostate tumor scanning in many clinical and preclinical epidemiological studies and describes possible pathogenetic biological mechanisms. Finally, this article discusses feasible clinical implications for the management, prevention, diagnosis, prognosis, and treatment of patients affected by metabolic syndrome and prostate cancer, with particular attention to the metformin action.

KW - Androgen deprivation therapy

KW - Carcinogenesis

KW - Hyperinsulinemia

KW - Insulin-growth factor-1

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=84883463960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883463960&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.04.009

DO - 10.1016/j.clgc.2013.04.009

M3 - Article

VL - 11

SP - 211

EP - 220

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -